AstraZeneca Pharmaceuticals v. Mosaic Health

Drug companies AstraZeneca and Eli Lilly ask the Supreme Court to review a Second Circuit antitrust case involving claimed lost profits and alleged coordination among businesses. The petition raises questions about suits based on indirect sales and whether lobbying or trade-association activity can plausibly suggest a conspiracy.

The case is pending, and oral argument has not been scheduled. No substantive justice or advocate reactions are available yet.

The case could affect when businesses may seek antitrust damages for profits they say they lost from sales that never occurred. For example, a company claiming it lost customers because of an alleged drug-industry conspiracy could face limits on its ability to sue.

The Court may decide whether to grant certiorari (the Court's decision to hear the case). No argument date or decision window is available; watch for a scheduling order or other Court action.

The case asks when companies can seek antitrust damages for lost profits tied to indirect sales that did not occur.

Businesses claiming lost sales, including companies in concentrated industries, could be affected. So could companies accused of coordinating through lobbying or trade associations.

The Supreme Court will first decide whether to grant certiorari (the decision to hear the case). Oral argument has not been scheduled.